Preventive Treatment of Episodic and Chronic Migraine
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01319825
Recruitment Status : Unknown
Verified March 2011 by California Medical Clinic for Headache. Recruitment status was: Not yet recruiting
This is an open label pilot study to determine whether milnacipran can reduce headache frequency in episodic and chronic migraine sufferers.
Condition or disease
Migraine With AuraMigraine Without AuraChronic Migraine
Patients with episodic migraine with and/or without aura and chronic migraine will be treated with 100 or 200 mg of milnacipran for a total of 4 months including a one month titration phase and a 3 month maintenance phase. Baseline (pre-treatment) and end-of-maintenance phase headache frequencies will be recorded. There is no placebo treatment in this study. In addition to headache frequencies, other parameters being measured include safety and tolerability.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Migraine with or without aura or chronic migraine.
Subject age 18 to 70.
At least 2 migraine attacks per month.
Willing ang able to give written informed consent.
Willing and able to complete the entire course of the study and to comply with study instructions.
Willing to taper and discontinue their current preventive medications.
Subject is pregnant, lactating or planning a pregnancy in the next year.
Subject is female of child-bearing potential and not taking adequate forms of birth control.
Significant medical or psychiatric disease or abnormal laboratory data that would preclude entry into this study.
Previous failure of four or more adequate trials of preventive medication.
Currently on any form of antidepressant for depression and not able to discontinue.
Currently demonstrating medication overuse headache.
Currently has uncontrolled narrow angle glaucoma.
Currently taking monoamine oxidase inhibitors.
Subject has a history of seizures.
Participation in an investigational drug study within the last 30 days or 5 half-lives, whichever is longer.
Migraine Disorders Migraine with Aura Migraine without Aura
Headache Disorders, Primary
Central Nervous System Diseases
Nervous System Diseases
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents